Yi-Ting Hsieh1, Minhaj Nur Alam2, David Le2, Chia-Chieh Hsiao3, Chang-Hao Yang4, Daniel L Chao5, Xincheng Yao2. 1. Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: ythyth@gmail.com. 2. Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois. 3. Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. 4. Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan; School of Medicine, National Taiwan University, Taipei, Taiwan. 5. Shiley Eye Institute, Department of Ophthalmology, University of California San Diego, San Diego, California.
Abstract
PURPOSE: To correlate quantitative OCT angiography (OCTA) biomarkers with clinical features and to predict the extent of visual improvement after ranibizumab treatment for diabetic macular edema (DME) with OCTA biomarkers. DESIGN: Retrospective, longitudinal study in Taiwan. PARTICIPANTS: Fifty eyes of 50 patients with DME and 22 eyes of 22 healthy persons, with the exception of cataract and refractive error, from 1 hospital. METHODS: Each eye underwent OCT angiography (RTVue XR Avanti System with AngioVue software version 2017.1; Optovue, Fremont, CA), and 3×3-mm2 en face OCTA images of the superficial layer and the deep layer were obtained at baseline and after 3 monthly injections of ranibizumab in the study group. OCT angiography images also were acquired from the control group. MAIN OUTCOME MEASURES: Five OCTA biomarkers, including foveal avascular zone (FAZ) area (FAZ-A), FAZ contour irregularity (FAZ-CI), average vessel caliber (AVC), vessel tortuosity (VT), and vessel density (VD), were analyzed comprehensively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) also were obtained. Student t tests were used to compare the OCTA biomarkers between the study group and the control group. Linear regression models were used to evaluate the correlations between the baseline OCTA biomarkers and the changes of BCVA and CRT after treatment. RESULTS: Eyes with DME had larger AVC, VT, FAZ-A, and FAZ-CI and lower VD than those in the control group (P < 0.001 for all). After the loading ranibizumab treatment, these OCTA biomarkers improved but did not return to normal levels. Among all biomarkers, higher inner parafoveal VD in the superficial layer at baseline correlated most significantly with visual gain after treatment in the multiple regression model with adjustment for CRT and ellipsoid zone disruption (P < 0.001). To predict visual improvement, outer parafoveal VD in the superficial layer at the baseline showed the largest area under the receiver operating characteristic curve (0.787; P = 0.004). No baseline OCTA biomarkers showed any significant correlation specifically with anatomic improvement. CONCLUSIONS: For eyes with DME, parafoveal VD in the superficial layer at baseline was an independent predictor for visual improvement after the loading ranibizumab treatment.
PURPOSE: To correlate quantitative OCT angiography (OCTA) biomarkers with clinical features and to predict the extent of visual improvement after ranibizumab treatment for diabetic macular edema (DME) with OCTA biomarkers. DESIGN: Retrospective, longitudinal study in Taiwan. PARTICIPANTS: Fifty eyes of 50 patients with DME and 22 eyes of 22 healthy persons, with the exception of cataract and refractive error, from 1 hospital. METHODS: Each eye underwent OCT angiography (RTVue XR Avanti System with AngioVue software version 2017.1; Optovue, Fremont, CA), and 3×3-mm2 en face OCTA images of the superficial layer and the deep layer were obtained at baseline and after 3 monthly injections of ranibizumab in the study group. OCT angiography images also were acquired from the control group. MAIN OUTCOME MEASURES: Five OCTA biomarkers, including foveal avascular zone (FAZ) area (FAZ-A), FAZ contour irregularity (FAZ-CI), average vessel caliber (AVC), vessel tortuosity (VT), and vessel density (VD), were analyzed comprehensively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) also were obtained. Student t tests were used to compare the OCTA biomarkers between the study group and the control group. Linear regression models were used to evaluate the correlations between the baseline OCTA biomarkers and the changes of BCVA and CRT after treatment. RESULTS: Eyes with DME had larger AVC, VT, FAZ-A, and FAZ-CI and lower VD than those in the control group (P < 0.001 for all). After the loading ranibizumab treatment, these OCTA biomarkers improved but did not return to normal levels. Among all biomarkers, higher inner parafoveal VD in the superficial layer at baseline correlated most significantly with visual gain after treatment in the multiple regression model with adjustment for CRT and ellipsoid zone disruption (P < 0.001). To predict visual improvement, outer parafoveal VD in the superficial layer at the baseline showed the largest area under the receiver operating characteristic curve (0.787; P = 0.004). No baseline OCTA biomarkers showed any significant correlation specifically with anatomic improvement. CONCLUSIONS: For eyes with DME, parafoveal VD in the superficial layer at baseline was an independent predictor for visual improvement after the loading ranibizumab treatment.
Authors: Wasim A Samara; Emil A T Say; Chloe T L Khoo; Timothy P Higgins; George Magrath; Sandor Ferenczy; Carol L Shields Journal: Retina Date: 2015-11 Impact factor: 4.256
Authors: Hamid-Reza Moein; Eduardo A Novais; Carl B Rebhun; Emily D Cole; Ricardo N Louzada; André J Witkin; Caroline R Baumal; Jay S Duker; Nadia K Waheed Journal: Retina Date: 2018-12 Impact factor: 4.256
Authors: Thomas S Hwang; Simon S Gao; Liang Liu; Andreas K Lauer; Steven T Bailey; Christina J Flaxel; David J Wilson; David Huang; Yali Jia Journal: JAMA Ophthalmol Date: 2016-04 Impact factor: 7.389
Authors: Tien Y Wong; Jennifer Sun; Ryo Kawasaki; Paisan Ruamviboonsuk; Neeru Gupta; Van Charles Lansingh; Mauricio Maia; Wanjiku Mathenge; Sunil Moreker; Mahi M K Muqit; Serge Resnikoff; Juan Verdaguer; Peiquan Zhao; Frederick Ferris; Lloyd P Aiello; Hugh R Taylor Journal: Ophthalmology Date: 2018-05-24 Impact factor: 12.079
Authors: Yansha Lu; Joseph M Simonett; Jie Wang; Miao Zhang; Thomas Hwang; Ahmed M Hagag; David Huang; Dengwang Li; Yali Jia Journal: Invest Ophthalmol Vis Sci Date: 2018-05-01 Impact factor: 4.799
Authors: Alice Y Kim; Zhongdi Chu; Anoush Shahidzadeh; Ruikang K Wang; Carmen A Puliafito; Amir H Kashani Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Brian D Krawitz; Erika Phillips; Richard D Bavier; Shelley Mo; Joseph Carroll; Richard B Rosen; Toco Y P Chui Journal: Transl Vis Sci Technol Date: 2018-07-12 Impact factor: 3.283
Authors: Jonathan F Russell; Hasenin Al-Khersan; Yingying Shi; Nathan L Scott; John W Hinkle; Kenneth C Fan; Cancan Lyu; William J Feuer; Giovanni Gregori; Philip J Rosenfeld Journal: Am J Ophthalmol Date: 2020-03-13 Impact factor: 5.258
Authors: Jonathan F Russell; Nathan L Scott; Justin H Townsend; Yingying Shi; Giovanni Gregori; Ashley M Crane; Harry W Flynn; Jayanth Sridhar; Philip J Rosenfeld Journal: Retina Date: 2021-08-01 Impact factor: 3.975